Cargando…
Reversal of P‐Glycoprotein‐mediated Paclitaxel Resistance by New Synthetic Isoprenoids in Human Bladder Cancer Cell Line
We isolated a paclitaxel‐resistant cell line (KK47/TX30) from a human bladder cancer cell line (KK47/WT) in order to investigate the mechanism of and reversal agents for paclitaxel resistance. KK47/TX30 cells exhibited 700‐fold resistance to paclitaxel and cross‐resistance to vinca alkaloids and top...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927134/ https://www.ncbi.nlm.nih.gov/pubmed/12359058 http://dx.doi.org/10.1111/j.1349-7006.2002.tb02481.x |
_version_ | 1783319032957501440 |
---|---|
author | Enokida, Hideki Gotanda, Takenari Oku, Shoichi Imazono, Yoshiharu Kubo, Hiroyuki Hanada, Toshikatsu Suzuki, Shigenori Inomata, Kouhei Kishiye, Takao Tahara, Yoshiyuki Nishiyama, Kenryu Nakagawa, Masayuki |
author_facet | Enokida, Hideki Gotanda, Takenari Oku, Shoichi Imazono, Yoshiharu Kubo, Hiroyuki Hanada, Toshikatsu Suzuki, Shigenori Inomata, Kouhei Kishiye, Takao Tahara, Yoshiyuki Nishiyama, Kenryu Nakagawa, Masayuki |
author_sort | Enokida, Hideki |
collection | PubMed |
description | We isolated a paclitaxel‐resistant cell line (KK47/TX30) from a human bladder cancer cell line (KK47/WT) in order to investigate the mechanism of and reversal agents for paclitaxel resistance. KK47/TX30 cells exhibited 700‐fold resistance to paclitaxel and cross‐resistance to vinca alkaloids and topoisomerase II inhibitors. Tubulin polymerization assay showed no significant difference in the ratio of polymerized α‐ and β‐tubulin between KK47/WT and KK47/TX30 cells. Western blot analysis demonstrated overexpression of P‐glycoprotein (P‐gp) and lung resistance‐related protein (LRP) in KK47/TX30 cells. Drug accumulation and efflux studies showed that the decreased paclitaxel accumulation in KK47/TX30 cells was due to enhanced paclitaxel efflux. Cell survival assay revealed that verapamil and cepharanthine, conventional P‐gp modulators, could completely overcome paclitaxel resistance. To investigate whether new synthetic isoprenoids could overcome paclitaxel resistance, we synthesized 31 isoprenoids based on the structure of N‐solanesyl‐N, N′‐bis(3,4‐dimethoxybenzyl)ethylenediamine (SDB), which could reverse multidrug resistance (MDR), as shown previously. Among those examined, trans‐N, N′‐bis(3,4‐dimethoxybenzyl)‐.N‐solanesyl‐l,2‐diaminocyclohexane (N‐5228) could completely reverse paclitaxel resistance in KK47/TX30 cells. N‐5228 inhibited photoaffinity labeling of P‐gp by [(3)H]azidopine, suggesting that N‐5228 could bind to P‐gp directly and could be a substrate of P‐gp. Next, we investigated structural features of these 31 isoprenoids in order to determine the structural requirements for the reversal of P‐gp‐mediated paclitaxel resistance, suggesting that the following structural features are important for overcoming paclitaxel resistance: (1) a basic structure of 8 to 10 isoprene units, (2) a cyclohexane ring or benzene ring within the framework, (3) two cationic sites in close proximity to each other, and (4) a benzyl group with 3, 4‐dimethoxy functionalities, which have moderate electron‐donating ability. These findings may provide valuable information for the development of P‐gp‐mediated MDR‐reversing agents. |
format | Online Article Text |
id | pubmed-5927134 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2002 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-59271342018-05-11 Reversal of P‐Glycoprotein‐mediated Paclitaxel Resistance by New Synthetic Isoprenoids in Human Bladder Cancer Cell Line Enokida, Hideki Gotanda, Takenari Oku, Shoichi Imazono, Yoshiharu Kubo, Hiroyuki Hanada, Toshikatsu Suzuki, Shigenori Inomata, Kouhei Kishiye, Takao Tahara, Yoshiyuki Nishiyama, Kenryu Nakagawa, Masayuki Jpn J Cancer Res Article We isolated a paclitaxel‐resistant cell line (KK47/TX30) from a human bladder cancer cell line (KK47/WT) in order to investigate the mechanism of and reversal agents for paclitaxel resistance. KK47/TX30 cells exhibited 700‐fold resistance to paclitaxel and cross‐resistance to vinca alkaloids and topoisomerase II inhibitors. Tubulin polymerization assay showed no significant difference in the ratio of polymerized α‐ and β‐tubulin between KK47/WT and KK47/TX30 cells. Western blot analysis demonstrated overexpression of P‐glycoprotein (P‐gp) and lung resistance‐related protein (LRP) in KK47/TX30 cells. Drug accumulation and efflux studies showed that the decreased paclitaxel accumulation in KK47/TX30 cells was due to enhanced paclitaxel efflux. Cell survival assay revealed that verapamil and cepharanthine, conventional P‐gp modulators, could completely overcome paclitaxel resistance. To investigate whether new synthetic isoprenoids could overcome paclitaxel resistance, we synthesized 31 isoprenoids based on the structure of N‐solanesyl‐N, N′‐bis(3,4‐dimethoxybenzyl)ethylenediamine (SDB), which could reverse multidrug resistance (MDR), as shown previously. Among those examined, trans‐N, N′‐bis(3,4‐dimethoxybenzyl)‐.N‐solanesyl‐l,2‐diaminocyclohexane (N‐5228) could completely reverse paclitaxel resistance in KK47/TX30 cells. N‐5228 inhibited photoaffinity labeling of P‐gp by [(3)H]azidopine, suggesting that N‐5228 could bind to P‐gp directly and could be a substrate of P‐gp. Next, we investigated structural features of these 31 isoprenoids in order to determine the structural requirements for the reversal of P‐gp‐mediated paclitaxel resistance, suggesting that the following structural features are important for overcoming paclitaxel resistance: (1) a basic structure of 8 to 10 isoprene units, (2) a cyclohexane ring or benzene ring within the framework, (3) two cationic sites in close proximity to each other, and (4) a benzyl group with 3, 4‐dimethoxy functionalities, which have moderate electron‐donating ability. These findings may provide valuable information for the development of P‐gp‐mediated MDR‐reversing agents. Blackwell Publishing Ltd 2002-09 /pmc/articles/PMC5927134/ /pubmed/12359058 http://dx.doi.org/10.1111/j.1349-7006.2002.tb02481.x Text en |
spellingShingle | Article Enokida, Hideki Gotanda, Takenari Oku, Shoichi Imazono, Yoshiharu Kubo, Hiroyuki Hanada, Toshikatsu Suzuki, Shigenori Inomata, Kouhei Kishiye, Takao Tahara, Yoshiyuki Nishiyama, Kenryu Nakagawa, Masayuki Reversal of P‐Glycoprotein‐mediated Paclitaxel Resistance by New Synthetic Isoprenoids in Human Bladder Cancer Cell Line |
title | Reversal of P‐Glycoprotein‐mediated Paclitaxel Resistance by New Synthetic Isoprenoids in Human Bladder Cancer Cell Line |
title_full | Reversal of P‐Glycoprotein‐mediated Paclitaxel Resistance by New Synthetic Isoprenoids in Human Bladder Cancer Cell Line |
title_fullStr | Reversal of P‐Glycoprotein‐mediated Paclitaxel Resistance by New Synthetic Isoprenoids in Human Bladder Cancer Cell Line |
title_full_unstemmed | Reversal of P‐Glycoprotein‐mediated Paclitaxel Resistance by New Synthetic Isoprenoids in Human Bladder Cancer Cell Line |
title_short | Reversal of P‐Glycoprotein‐mediated Paclitaxel Resistance by New Synthetic Isoprenoids in Human Bladder Cancer Cell Line |
title_sort | reversal of p‐glycoprotein‐mediated paclitaxel resistance by new synthetic isoprenoids in human bladder cancer cell line |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927134/ https://www.ncbi.nlm.nih.gov/pubmed/12359058 http://dx.doi.org/10.1111/j.1349-7006.2002.tb02481.x |
work_keys_str_mv | AT enokidahideki reversalofpglycoproteinmediatedpaclitaxelresistancebynewsyntheticisoprenoidsinhumanbladdercancercellline AT gotandatakenari reversalofpglycoproteinmediatedpaclitaxelresistancebynewsyntheticisoprenoidsinhumanbladdercancercellline AT okushoichi reversalofpglycoproteinmediatedpaclitaxelresistancebynewsyntheticisoprenoidsinhumanbladdercancercellline AT imazonoyoshiharu reversalofpglycoproteinmediatedpaclitaxelresistancebynewsyntheticisoprenoidsinhumanbladdercancercellline AT kubohiroyuki reversalofpglycoproteinmediatedpaclitaxelresistancebynewsyntheticisoprenoidsinhumanbladdercancercellline AT hanadatoshikatsu reversalofpglycoproteinmediatedpaclitaxelresistancebynewsyntheticisoprenoidsinhumanbladdercancercellline AT suzukishigenori reversalofpglycoproteinmediatedpaclitaxelresistancebynewsyntheticisoprenoidsinhumanbladdercancercellline AT inomatakouhei reversalofpglycoproteinmediatedpaclitaxelresistancebynewsyntheticisoprenoidsinhumanbladdercancercellline AT kishiyetakao reversalofpglycoproteinmediatedpaclitaxelresistancebynewsyntheticisoprenoidsinhumanbladdercancercellline AT taharayoshiyuki reversalofpglycoproteinmediatedpaclitaxelresistancebynewsyntheticisoprenoidsinhumanbladdercancercellline AT nishiyamakenryu reversalofpglycoproteinmediatedpaclitaxelresistancebynewsyntheticisoprenoidsinhumanbladdercancercellline AT nakagawamasayuki reversalofpglycoproteinmediatedpaclitaxelresistancebynewsyntheticisoprenoidsinhumanbladdercancercellline |